Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Share-based Compensation: 2022-2025

Historic Share-based Compensation for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to $7.2 million.

  • Centessa Pharmaceuticals' Share-based Compensation fell 14.89% to $7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.4 million, marking a year-over-year decrease of 3.96%. This contributed to the annual value of $33.5 million for FY2024, which is 14.13% up from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported Share-based Compensation of $7.2 million as of Q3 2025, which was down 9.50% from $7.9 million recorded in Q2 2025.
  • Over the past 5 years, Centessa Pharmaceuticals' Share-based Compensation peaked at $8.6 million during Q2 2024, and registered a low of $5.6 million during Q2 2022.
  • Moreover, its 3-year median value for Share-based Compensation was $7.9 million (2025), whereas its average is $7.8 million.
  • In the last 5 years, Centessa Pharmaceuticals' Share-based Compensation rose by 28.73% in 2023 and then fell by 14.89% in 2025.
  • Over the past 4 years, Centessa Pharmaceuticals' Share-based Compensation (Quarterly) stood at $6.6 million in 2022, then grew by 12.29% to $7.4 million in 2023, then increased by 12.09% to $8.3 million in 2024, then decreased by 14.89% to $7.2 million in 2025.
  • Its last three reported values are $7.2 million in Q3 2025, $7.9 million for Q2 2025, and $7.9 million during Q1 2025.